智通财经APP讯，嘉和生物-B(06998)发布2024年度业绩，收益2.06亿元(人民币，下同)，上年同期为0;该变动乃主要由于与TRC 2004, Inc.签订的许可及股权协议。净亏损5297.4万元，同比收窄92.2%。
研发开支同比减少64.1%至2.028亿元，主要由于研发人员的雇员福利开支减少;集团的新药研发费及临床试验开支减少;及所用原材料及耗料减少。
在报告期内集团进一步优化架构，并通过多种灵活的外部合作形式，成功实现企业的轻资产模式，降低运营成本。降本增效的同时，积极开展战略合作，签署合并协议，并达成多个管线商业开发合作，聚焦推进核心管线开发和新药报批。
更多港股重磅资讯，下载智通财经app
更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.